Several studies on neoadjuvant treatment of patients with HER2-positive breast cancer have shown that PIK3CA mutations can be associated with lower pCR rates [18], more marked in estrogen receptor (ER)-positive cancer [19], and shorter disease-free survival (DFS) [17]. This evidence concerns the gene PIK3CA and breast carcinoma.